Core Viewpoint - The performance of Spring Medical has shown significant recovery after the impact of centralized procurement, with notable increases in revenue and net profit in recent quarters [2][3][12]. Financial Performance - In Q3 2024, Spring Medical reported revenue of 756 million yuan, a year-on-year increase of 48.75%, and a net profit of 192 million yuan, up 213.21% year-on-year [2]. - The company's Q3 revenue reached 268 million yuan, marking a 109.51% increase year-on-year, and the net profit turned positive at 77.06 million yuan [2][3]. - In Q1 2023, Spring Medical achieved a revenue of 230 million yuan, a slight increase of 3.6%, and a net profit of 58 million yuan, up 5.2% [3]. Market Trends - The orthopedic consumables industry is experiencing a recovery, with Spring Medical's revenue growth in Q2 2025 reaching 62.85%, outperforming peers [6]. - The global orthopedic medical device market is projected to grow to $62.22 billion in 2024 and exceed $94 billion by 2032, with a stable annual growth rate of 5.3% [12]. Stock Performance - Spring Medical's stock price has increased by 122.13% year-to-date as of October 31, 2024, reflecting renewed market confidence [2]. - The stock experienced a significant rise in May, June, and July 2024, with respective increases of 17.69%, 12.18%, and 29.85% [9]. Strategic Developments - Spring Medical has been actively expanding its international market presence, with overseas revenue accounting for 40% of total revenue in the first half of 2025 [14]. - The company has received multiple regulatory approvals for its products, including the FDA 510(K) approval for its knee prosthesis system, enhancing its competitive edge in international markets [15]. Product Development - Spring Medical has made significant advancements in product development, with 35 new registrations obtained in the first nine months of the year, and R&D investment accounting for 11.44% of revenue [13]. - The company is the first in China to have a chemical vapor deposition manufacturing process for porous tantalum metal implants, breaking foreign monopolies [13].

Core Viewpoint - Spring Medical (688236) has shown significant growth in revenue and net profit for the first three quarters of 2025, indicating strong operational performance and potential investment opportunities. Financial Performance - For the first three quarters of 2025, the company achieved revenue of 756 million yuan, a year-on-year increase of 48.75% [2] - The net profit attributable to shareholders reached 192 million yuan, reflecting a substantial year-on-year growth of 213.21% [2] - The net profit for the third quarter alone was 77.06 million yuan, marking a remarkable increase of 531.12% compared to the same period last year [5] Shareholder and Stock Information - As of September 30, 2025, the number of shareholders increased to 6,149, up by 4.11% from June 30, 2025 [3] - The average number of shares held per shareholder decreased from 48,800 to 46,900, with an average holding value of 1.1684 million yuan [3] Dividend and Corporate Governance - The company plans to distribute a cash dividend of 2.10 yuan per 10 shares (including tax), totaling approximately 80.26 million yuan, which represents 41.90% of the net profit [3][5] - The board has approved a proposal to abolish the supervisory board, transferring its functions to the audit committee of the board, pending shareholder approval [3][5] Asset Impairment - For the first three quarters of 2025, the company recognized an asset impairment provision totaling 45.71 million yuan, primarily due to bad debt losses and inventory write-downs [3]

Core Viewpoint - Spring Medical is a leading company in the domestic orthopedic implant medical device sector, focusing on joint prosthetics and spinal implants, with a strong technical and full industry chain advantage [1] Group 1: Business Performance - In Q3 2025, Spring Medical achieved a revenue of 756 million yuan, ranking 25th among 50 companies in the industry, with the industry leader, Yingke Medical, generating 7.425 billion yuan [2] - The net profit for the same period was 192 million yuan, placing the company 20th in the industry, while the top performer, Lepu Medical, reported a net profit of 996 million yuan [2] - The company reported a year-on-year revenue growth of 48.8% and a net profit growth of 213.2% for the first nine months of 2025, driven by international market expansion and increased export revenue [6] Group 2: Financial Ratios - As of Q3 2025, Spring Medical's debt-to-asset ratio was 15.65%, lower than the previous year's 19.98% and below the industry average of 23.66%, indicating strong solvency [3] - The gross profit margin for the same period was 67.27%, slightly down from 69.30% year-on-year but significantly higher than the industry average of 48.78%, reflecting strong profitability [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 4.11% to 6,149, while the average number of circulating A-shares held per household decreased by 3.95% to 46,900 shares [5] Group 4: Management Compensation - The chairman, Shi Wenling, received a salary of 341,100 yuan in 2024, a decrease of 58,100 yuan from 2023, while the general manager, Shi Chunsheng, saw an increase in salary to 525,700 yuan [4] Group 5: Future Outlook - The company plans to distribute a cash dividend of 2.10 yuan per 10 shares, totaling 80.26 million yuan, and forecasts net profits of 280 million yuan, 360 million yuan, and 440 million yuan for 2025 to 2027 [6] - New product approvals in sports medicine, robotics, and dentistry are expected to contribute to future revenue growth [7]

Core Insights - The medical device sector experienced a rise of 1.13% on October 31, with Caina Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3954.79, down 0.81%, while the Shenzhen Component Index closed at 13378.21, down 1.14% [1] Medical Device Sector Performance - Caina Co., Ltd. (301122) saw a closing price of 30.38, with a significant increase of 19.98% and a trading volume of 91,000 shares, amounting to a transaction value of 259 million [1] - Spring Medical (688236) closed at 28.88, up 14.47%, with a trading volume of 84,200 shares and a transaction value of 235 million [1] - ZhenDe Medical (603301) closed at 95.00, increasing by 9.07% with a trading volume of 211,900 shares, resulting in a transaction value of 1.951 billion [1] - Other notable performers included TuoJing Life (300642) with an 8.81% increase, and Rejing Bio (688068) with an 8.70% increase [1] Capital Flow Analysis - The medical device sector saw a net inflow of 475 million from institutional investors, while retail investors experienced a net outflow of 108 million [2][3] - Major stocks like Mindray Medical (300760) had a net inflow of 262 million from institutional investors, but a net outflow of 1.27 billion from retail investors [3] - Other stocks such as Furuishi (300049) and Lepu Medical (300003) also showed significant net inflows from institutional investors, indicating strong institutional interest [3]

Group 1 - Spring Medical (01858.HK) has seen a significant increase in its stock price, rising over 10% [1] - As of the latest update, the stock is up 10.66%, trading at 18.37 HKD [1] - The trading volume reached 45.461 million HKD [1]

Core Viewpoint - Spring Medical (01858) experienced a significant stock increase of over 10%, attributed to strong financial performance in the first three quarters of 2025, with notable growth in revenue and net profit [1] Financial Performance - The company reported a revenue of 756 million yuan, representing a year-on-year increase of 48.75% [1] - Net profit attributable to shareholders reached 192 million yuan, showing a substantial year-on-year growth of 213.21% [1] - In the third quarter alone, revenue was 268 million yuan, reflecting a remarkable year-on-year growth of 109.51% [1] - The net profit for the third quarter was 77.06 million yuan, marking a turnaround from losses to profitability [1] Market Expansion and Competitive Advantage - Huatai Securities noted that the company's rapid growth in the third quarter is primarily due to its steady progress in international market expansion and increasing export revenue [1] - The company has successfully passed CE annual system audits and supervision audits for its hip, knee, and spine product lines, indicating strong international market competitiveness [1] - The knee prosthesis system received FDA 510(K) approval, showcasing the company's technological advantages and establishing a foundation for sustained international sales growth [1]

Core Viewpoint - Spring Medical (01858) has experienced a significant stock price increase of over 10%, attributed to strong financial performance in Q3 2025, with notable revenue and profit growth [1] Financial Performance - The company reported a revenue of 756 million yuan for the first three quarters of 2025, representing a year-on-year increase of 48.75% [1] - Net profit attributable to shareholders reached 192 million yuan, showing a substantial year-on-year growth of 213.21% [1] - In Q3 alone, the company achieved a revenue of 268 million yuan, marking a remarkable year-on-year increase of 109.51% [1] - The net profit for Q3 was 77.06 million yuan, indicating a turnaround from loss to profit [1] Market Expansion and Product Development - Huatai Securities attributes the rapid growth in Q3 to the company's steady progress in international market expansion and increasing export revenue [1] - The company has successfully passed CE annual system audits and supervision audits for its hip, knee, and spine product lines, indicating strong international competitiveness [1] - The knee prosthesis system has received FDA 510(k) approval, showcasing the company's technological advantages and establishing a foundation for continued growth in international sales [1]

Company Overview - Spring Medical is a Chinese company primarily engaged in the research, production, and sales of implantable orthopedic medical devices, with a focus on joint prosthetics and spinal implants [1] - The company was established on February 12, 1998, and went public on December 30, 2021 [1] - Its main products include hip, knee, shoulder, and elbow joint prosthetics, as well as a full range of spinal fixation systems [1] - The company's revenue composition is predominantly from medical device products at 99.89%, with a minor contribution of 0.11% from other sources [1] Market Performance - As of October 31, Spring Medical's stock price increased by 5.03%, reaching 26.50 CNY per share, with a trading volume of 26.14 million CNY and a turnover rate of 0.35% [1] - The total market capitalization of Spring Medical is 10.165 billion CNY [1] Shareholder Information - Among the top circulating shareholders, one fund from China Europe Fund, the China Europe Prosperity Selected Mixed A (020876), entered the top ten in the third quarter, holding 2.8326 million shares, which is 0.74% of the circulating shares [2] - The estimated floating profit for this fund today is approximately 3.5974 million CNY [2] Fund Performance - The China Europe Prosperity Selected Mixed A fund, managed by Zhang Xueming, has a total asset size of 6.741 billion CNY [3] - Since its inception, the fund has achieved a return of 70.66%, with a year-to-date return of 52.9% and a one-year return of 58.85% [2][3]

Core Insights - Spring Medical (688236.SH) reported a total revenue of 756 million yuan for Q3 2025, with a net profit attributable to shareholders of 192 million yuan and a net cash inflow from operating activities of 175 million yuan [1]. Financial Performance - The company's latest debt-to-asset ratio stands at 15.65% [3]. - The gross profit margin is 67.27%, which is a decrease of 2.03 percentage points compared to the same period last year [3]. - The return on equity (ROE) is reported at 6.42% [3]. - The diluted earnings per share (EPS) is 0.50 yuan [3]. - The total asset turnover ratio is 0.22 times, ranking 79th among disclosed peers [3]. - The inventory turnover ratio is 0.44 times, ranking 127th among disclosed peers [3]. Shareholder Structure - The number of shareholders is 6,164, with the top ten shareholders holding a total of 249 million shares, accounting for 64.88% of the total share capital [3]. - The top ten shareholders and their respective holdings are as follows: - Shi Chunbao: 31.3 million shares - Yue Mujun: 24.8 million shares - Beijing Panmao Investment Management Co., Ltd.: 4.50 million shares - Hong Kong Central Clearing Limited: 0.77 million shares - Huaxia Bank Co., Ltd.: 0.74 million shares - Huang Dong: 0.66 million shares - Beijing Panmao Investment Management Co., Ltd.: 0.65 million shares - Agricultural Bank of China: 0.55 million shares - Huatai Securities Asset Management: 0.43 million shares - Beijing Chunli Zhengda Medical Device Co., Ltd.: 0.36 million shares [3].

（股 份 代 號：1858） 將於2025年11月19日舉行之H股類別股東大會之代表委任表格 本人╱吾等 （附註1） ， 地址為 ， 為北京市春立正達醫療器械股份有限公司（「本公司」）股本中每股面值人民幣1.00元之 股 H股 （附註2） 之登記持有人，茲委任H股類別股東大會主席或 （附註3） ， 為本人╱吾等之受委任代表，代表本人╱吾等出席將於2025年11月19日（星期三）下午二時正（或緊隨於同日舉行的本公司A股類 別股東大會結束後）在中國北京市通州區通州經濟開發區南區鑫覓西二路10號舉行的H股類別股東大會及其任何續會，以考慮 並酌情通過召開H股類別股東大會通知所載之決議案，並於H股類別股東大會及其任何續會上代表本人╱吾等以本人╱吾等之 名義依照以下指示 （附註4） 就該決議案投票。 有關決議案的進一步詳情載於本公司日期為2025年10月30日的通函內。 | | 特別決議案 | 贊成 | （附註4） | 反對 | （附註4） | 棄權 | （附註4） | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. | 審議及批准取消監事會及建議修訂章程細則 ...